Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM.

Tian J, Yang Y, Yu Z, Gao Y, Zong X, Wu Q, Su H, Cao W, Xu D

Hormones (Athens, Greece)11 Apr 2025Cited by 3 (Europe PMC)

PMID40214965DOI10.1007/s42000-025-00649-zPepBankPUB-40214965

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

01HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, dulaglutide plus probiotics reduced HbA1c more than dulaglutide plus placebo.
In plain wordsIn adults with diabetes, dulaglutide plus probiotics reduced HbA1c more than dulaglutide plus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−1.06%
combination
HbA1c change
−0.35%
dulaglutide plus placebo
Source sentences
Summary
The intervention group showed greater reductions in HbA1c (- 1.06% vs. -0.35%, P = 0.028), FPG (- 4.16 vs. -3.92 mmol/L, P = 0.010), and inflammatory markers (TNF-α: -43.6% vs. -33.3%, P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496501
02HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, dulaglutide plus probiotics reduced fasting plasma glucose more than dulaglutide plus placebo.
In plain wordsIn adults with diabetes, dulaglutide plus probiotics reduced fasting glucose more than dulaglutide plus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting plasma glucose
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Fasting plasma glucose change
−4.16 mmol/L
dulaglutide plus probiotics
Fasting plasma glucose change
−3.92 mmol/L
dulaglutide plus placebo
Source sentences
Summary
The intervention group showed greater reductions in HbA1c (- 1.06% vs. -0.35%, P = 0.028), FPG (- 4.16 vs. -3.92 mmol/L, P = 0.010), and inflammatory markers (TNF-α: -43.6% vs. -33.3%, P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496502
03HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialMechanism
In adults with type 2 diabetes, dulaglutide plus probiotics reduced TNF-alpha more than dulaglutide plus placebo.
In plain wordsIn adults with diabetes, dulaglutide plus probiotics reduced TNF-alpha more than dulaglutide plus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTNF-alpha
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Inflammation markers · Immune and inflammation
Measurements
TNF-alpha change
−43.6%
dulaglutide plus probiotics
TNF-alpha change
−33.3%
dulaglutide plus placebo
Source sentences
Summary
The intervention group showed greater reductions in HbA1c (- 1.06% vs. -0.35%, P = 0.028), FPG (- 4.16 vs. -3.92 mmol/L, P = 0.010), and inflammatory markers (TNF-α: -43.6% vs. -33.3%, P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496503
04HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, dulaglutide plus probiotics improved HOMA-beta more than dulaglutide plus placebo.
In plain wordsIn adults with diabetes, dulaglutide plus probiotics improved pancreatic cell function more than dulaglutide plus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHOMA-beta
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
HOMA-beta change
34.7%
dulaglutide plus probiotics
HOMA-beta change
23.1%
dulaglutide plus placebo
Source sentences
Summary
Pancreatic beta-cell function improved significantly (HOMA-β: +34.7% vs. +23.1%, P = 0.034), with increased beneficial gut microbiota (Lactobacillus: +2.1 × 10⁶ vs. +1.3 × 10⁶ CFU/g, P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496504
05HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialMechanism
In adults with type 2 diabetes, dulaglutide plus probiotics increased gut Lactobacillus more than dulaglutide plus placebo.
In plain wordsIn adults with diabetes, dulaglutide plus probiotics increased gut Lactobacillus more than dulaglutide plus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGut Lactobacillus abundance
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Gut microbiota · Gastrointestinal
Measurements
Lactobacillus change
2.1 ×10⁶ CFU/g
dulaglutide plus probiotics
Lactobacillus change
1.3 ×10⁶ CFU/g
dulaglutide plus placebo
Source sentences
Summary
Pancreatic beta-cell function improved significantly (HOMA-β: +34.7% vs. +23.1%, P = 0.034), with increased beneficial gut microbiota (Lactobacillus: +2.1 × 10⁶ vs. +1.3 × 10⁶ CFU/g, P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496505
06HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, hypertension incidence was 0% with dulaglutide plus probiotics versus 13.3% with dulaglutide plus placebo.
In plain wordsIn adults with diabetes, hypertension occurred in 0% with dulaglutide plus probiotics versus 13.3% with dulaglutide plus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHypertension incidence
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Blood pressure · Cardiovascular
Measurements
Hypertension incidence
0%
dulaglutide plus probiotics
Hypertension incidence
13.3%
dulaglutide plus placebo
Source sentences
Summary
Hypertension incidence (0% vs. 13.3%, P = 0.038) and dyslipidemia (0% vs. 16.7%, P = 0.020) were lower in the intervention group.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496506
07HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, dyslipidemia incidence was 0% with dulaglutide plus probiotics versus 16.7% with dulaglutide plus placebo.
In plain wordsIn adults with diabetes, abnormal lipids occurred in 0% with dulaglutide plus probiotics versus 16.7% with dulaglutide plus placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDyslipidemia incidence
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Lipids · Metabolic and weight
Measurements
Dyslipidemia incidence
0%
dulaglutide plus probiotics
Dyslipidemia incidence
16.7%
dulaglutide plus placebo
Source sentences
Summary
Hypertension incidence (0% vs. 13.3%, P = 0.038) and dyslipidemia (0% vs. 16.7%, P = 0.020) were lower in the intervention group.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496507
08HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes, both dulaglutide plus probiotics and dulaglutide plus placebo were well tolerated.
In plain wordsIn adults with diabetes, both dulaglutide regimens were well tolerated.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTolerability
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Adverse events · Whole body
Source sentences
Summary
Both regimens were well-tolerated, with no severe hypoglycemia or renal/hepatic toxicity.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496508
09HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes, neither dulaglutide plus probiotics nor dulaglutide plus placebo produced severe hypoglycemia.
In plain wordsIn adults with diabetes, neither dulaglutide regimen produced severe low blood sugar.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSevere hypoglycemia
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Both regimens were well-tolerated, with no severe hypoglycemia or renal/hepatic toxicity.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496509
10HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes, neither dulaglutide plus probiotics nor dulaglutide plus placebo produced renal toxicity.
In plain wordsIn adults with diabetes, neither dulaglutide regimen produced kidney toxicity.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableRenal toxicity
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Adverse events · Kidney and urinary
Source sentences
Summary
Both regimens were well-tolerated, with no severe hypoglycemia or renal/hepatic toxicity.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496510
11HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes, neither dulaglutide plus probiotics nor dulaglutide plus placebo produced hepatic toxicity.
In plain wordsIn adults with diabetes, neither dulaglutide regimen produced liver toxicity.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHepatic toxicity
Study
n = 60
Comparator
Dulaglutide plus placebo
Outcome group
Adverse events · Liver
Source sentences
Summary
Both regimens were well-tolerated, with no severe hypoglycemia or renal/hepatic toxicity.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty overweight/obese adults with T2DM (HbA1c 6.5-11%, BMI ≥ 24 kg/m²) were randomized to a control group (dulaglutide 1.5 mg/week + placebo) or an intervention group (dulaglutide 1.5 mg/week + probiotics containing Bifidobacterium longum, 2 × 10⁹ CFU/dose) for 12 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4021496511

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Comparative evaluation of dulaglutide alone vs. dulaglutide combined with probiotics on cardiovascular risk factors in T2DM.

Summary

Results from this study11

Studies that did not test the peptide alone11

Version history

Subjects

Publication types

MeSH terms

Keywords